Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Upamostat - Link Health Group/RedHill Biopharma

Next Previous
Drug Profile

Upamostat - Link Health Group/RedHill Biopharma

Alternative Names: Mesupron; RHB-107; WX-671

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wilex
  • Developer Heidelberg Pharma AG; Link Health Group; RedHill Biopharma; WILEX AG
  • Class Amines; Antineoplastics; Antivirals; Imides; Piperazines; Small molecules; Sulfonamides
  • Mechanism of Action Serine endopeptidase inhibitors; Urokinase-type plasminogen activator inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • Phase II Breast cancer; Pancreatic cancer
  • Clinical Phase Unknown Gastrointestinal disorders
  • Preclinical Cholangiocarcinoma; Ebola virus infections; Influenza virus infections
  • No development reported Cancer; Solid tumours
  • Discontinued Head and neck cancer

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for preclinical development in Solid-tumours in China (PO, Capsule)
  • 02 Aug 2023 RedHill plans a phase III external non-dilutive funding trial for COVID 2019 infections US, Thailand, Ivory Coast, South Africa and Uganda
  • 31 Jul 2023 Redhill Biopharma receives FDA clearance to start phase II trial
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top